Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS GLP-1 Dulaglutide “Catalyst of Growth,” SGLT-2 Empagliflozin Will Be Successful Despite Later Launch: Lilly Diabetes President
November 12, 2013
-
BUSINESS 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End
November 11, 2013
-
BUSINESS Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
-
REGULATORY “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
-
REGULATORY Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs
November 7, 2013
-
BUSINESS Japan ARB Market Gets Back on Growth Track in April-September; No Major Impact from Diovan Woes
November 6, 2013
-
ORGANIZATION Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads
November 5, 2013
-
ACADEMIA Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
-
ACADEMIA Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
-
BUSINESS Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
-
REGULATORY New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
-
ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
-
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
-
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
-
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
-
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
-
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
-
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
-
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
-
REGULATORY MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…